This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Mackenzies Smelling Salts

OTC
Read time: 1 mins
Last updated: 03 Jul 2020
...
 

Summary of product characteristics


1. Name of the medicinal product

MACKENZIES SMELLING SALTS


2. Qualitative and quantitative composition

Contains not less than 8.820g Ammonia Liquor 880/890 and 0.539g Eucalyptus Oil.

For a full list of excipients, see section 6.1.


3. Pharmaceutical form

White granules.


4.1. Therapeutic indications

1) Traditionally used for the symptomatic relief of catarrh and head colds.


4.2. Posology and method of administration

Posology

Inhale vapour through nostrils as required.

Do not use for children under 3 months of age.

Method of Administration

Inhalant.


4.3. Contraindications

Do not use for children under 3 months of age.


4.4. Special warnings and precautions for use

None known.

The product labelling includes the following statements:

Not to be taken.

If symptoms persist consult your doctor.

Keep out of the reach and sight of children.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

No special precautions are considered necessary.


4.7. Effects on ability to drive and use machines

None known.


4.8. Undesirable effects

None known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.


4.9. Overdose

No special requirements are anticipated.


5.1. Pharmacodynamic properties

ATC code:R01A X

Ammonia is employed in the product as a reflex stimulant.

Eucalyptus oil is an essential oil.


5.2. Pharmacokinetic properties

Not applicable.


5.3. Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


6.1. List of excipients

Also contains glycerol, soft soap, tapioca, water.


6.2. Incompatibilities

None known.


6.3. Shelf life

Shelf-life

Three years from the date of manufacture.

Shelf-life after dilution/reconstitution

Not applicable.

Shelf-life after first opening

Not applicable.


6.4. Special precautions for storage

Store in a cool place.


6.5. Nature and contents of container

The product container is a uniquely-shaped amber glass bottle with black polypropylene cap with foil wad or black urea formaldehyde cap with polycone.

Pack size: 17ml


6.6. Special precautions for disposal and other handling

Not applicable.

Administrative Data


7. Marketing authorisation holder

TEVA UK Limited

Brampton Road

Hampden Park

Eastbourne

East Sussex

BN22 9AG

United Kingdom


8. Marketing authorisation number(s)

PL 00289/2207


9. Date of first authorisation/renewal of the authorisation

16.10.86 (Product Licence of Right issued: 27.7.73)

Renewed: 14.5.92; 11.7.97


10. Date of revision of the text

22/06/2020

4.1 Therapeutic indications

1) Traditionally used for the symptomatic relief of catarrh and head colds.

4.2 Posology and method of administration

Posology

Inhale vapour through nostrils as required.

Do not use for children under 3 months of age.

Method of Administration

Inhalant.

4.3 Contraindications

Do not use for children under 3 months of age.

4.4 Special warnings and precautions for use

None known.

The product labelling includes the following statements:

Not to be taken.

If symptoms persist consult your doctor.

Keep out of the reach and sight of children.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

No special precautions are considered necessary.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

None known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).